Treatment of metastatic melanoma using Interleukin-2 alone or in conjunction with vaccines

Clinical Cancer Research

Volumn 14, Issue 17, 2008, Pages 5610-5618

  Smith, Franz O ^a   Downey, Stephanie G ^a   Klapper, Jacob A ^a   C Yang, James ^a   Sherry, Richard M ^a   Royal, Richard E ^a   Kammula, Udai S ^a   Hughes, Marybeth S ^a   Restifo, Nicholas P ^a   Levy, Catherine L ^a   E White, Donald ^a   Steinberg, Seth M ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MELANOMA VACCINE; CANCER VACCINE; MELANOCYTE LINEAGE SPECIFIC ANTIGEN GP100; MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100; MEMBRANE PROTEIN; TUMOR ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT RESPONSE; CHILD; IMMUNOLOGY; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; SKIN TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; CHILD; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 53049088033     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0116     Document Type: Article

References (27)

1. Jemal A, Siegel R. Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57: 43-66.
2. Balch CM, Atkins MB, Sober AJ. Cutaneous melanoma. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer. Principles & practice of oncology. 7th ed. Philadelphia: Lippincott-Raven Publishers; 2005. p. 1754.
3. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.
4. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleu-kin 2. JAMA1994;271:907-13.
5. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate anti-tumor immune responses in patients with metastatic melanoma. Clin Cancer Res 2003;9:2973-80.
6. Rosenberg SA, Yang JC, Sherry RM, et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melano-cyte antigen. Hum GeneTher 2003;14:709-14.
7. Rosenberg SA, Zhai Y, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998;90:1894-900.
8. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
9. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004;54:131 -49; quiz 82-4.
10. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
12. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 1996;157:2539-48.
13. Kawakami Y, Robbins PF, Wang X, et al. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol 1998;161:6985-92.
14. Rosenberg SA,Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
15. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996;56:4749-57.
16. Kammula US, Lee KH, Riker AI, et al. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 1999;163:6867-75.
17. Rosenberg SA,Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998;228:307-19.
18. Anderson PM, Sorenson MA. Effects of route and formulation on clinical pharmacokinetics of interleu-kin-2. Clin Pharmacokinet1994;27:19-31.
19. Atzpodien J, Korfer A, Evers P, et al. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biotherapy1990;2:18-26.
20. Atkins MB. Interleukin-2: clinical applications. Semin Oncol 2002;29:12-7.
21. Karp SE. Low-dose intravenous bolus interleukin-2 with interferon-α therapy for metastatic melanoma and renalcellcarcinoma.JImmunother1998;21:56- 61.
22. Tagliaferri P, Barile C, Caraglia M, et al. Daily low- dose subcutaneous recombinant interleukin-2 by alternate weekly administration: antitumor activity and immunomodulatory effects. Am J Clin Oncol 1998;21:48-53.
23. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001;19:3477-82.
24. Royal RE, Steinberg SM, Krouse RS, et al. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am 1996;2:91-8.
25. Krouse RS, Royal RE, Heywood G, et al. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J ImmunotherEmphasisTumorImmunol1995;18:272-8.
26. Kruit WH, Goey SH, Lamers CH, et al. High-dose regimen of interleukin-2 and interferon-α in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer. J Immunother1997;20:312-20.
27. Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunother 2001;24:287-93.